|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma显示文摘BACKGROUND: Nonalcoholic fatty liver disease (NAFLD), especially nonalcoholic steatohepatitis, is a recognized risk factor for hepatocellular carcinoma (HCC). However, detailed analysis of the clinical features in patients with NAFLD and their association with HCC is lacking. This study aimed to update the clinical features of patients with NAFLD-associated HCC. DATA SOURCES: The clinical data of patients with NAFLD- associated HCC from 25 studies published between 1990 and 2010 in the Pubmed database were comprehensively reviewed. RESULTS: In a total of 169 patients with NAFLD-associated HCC, 72.8% were male. The median age at abnormal liver function tests and diagnosis of NAFLD and HCC was 60, 64 and 67 years, respectively. Most patients were obese (75%) and diabetic (59.8%), 32.3% had dyslipidemia, and 53% had hypertension. Nearly all patients (98.6%, 71/72) were complicated with at least one metabolic disorder. The majority (76%) of the HCC patients had a solitary tumor nodule, with the tumor size ranging from 0.8 to 20 cm in diameter (mean 3.4 cm). Most (61.1%) of the patients had moderately-differentiated HCC. In 40.2% of the patients, HCC occurred in the absence of cirrhosis. Among 130 patients, 57.7% underwent hepatectomy and 14.6% received liver transplantation. The mean follow-up of the treated patients for 25 months showed that 32.4% (24/74) died and 18.8% (9/48) had recurrence. CONCLUSIONS: Patients with NAFLD-associated HCC are usually accompanied with metabolic disorders. Regular surveillance in patients with NAFLD for HCC is necessary, especially for elderly men with metabolic syndrome. | Xiao-Yan Duan, Liang Qiao and Jian-Gao Fan Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China Storr Liver Unit at the Westmead Millennium Institute, the University of Sydney at Westmead Hospital, Westmead, NSW 2145, Australia | 2012 | Hepatobiliary & Pancreatic Diseases International2012，11，1： | 16 |
| 2 | Distribution,function and physiological role of melatonin in the lower gut显示文摘Melatonin is a hormone with endocrine, paracrine andautocrine actions. It is involved in the regulation of multiple functions, including the control of the gastroin-testinal (GI) system under physiological and pathophys-iological conditions. Since the gut contains at least 400times more melatonin than the pineal gland, a reviewof the functional importance of melatonin in the gutseems useful, especially in the context of recent clinicaltrials. Melatonin exerts its physiological effects throughspecific membrane receptors, named melatonin-1 re-ceptor (MT1), MT2 and MT3. These receptors can befound in the gut and their involvement in the regulationof GI motility, inflammation and pain has been reportedin numerous basic and clinical studies. Stable levels ofmelatonin in the lower gut that are unchanged follow-ing a pinealectomy suggest local synthesis and, further more, implicate physiological importance of endogenous melatonin in the GI tract. Presently, only a small number of human studies report possible beneficial and also possible harmful effects of melatonin in case reports and clinical trials. These human studies include patients with lower GI diseases, especially patients with irritable bowel syndrome, inflammatory bowel disease and colorectal cancer. In this review, we summarize the presently available information on melatonin effects in the lower gut and discuss available in vitro and in vivo data. We furthermore aim to evaluate whether melatonin may be useful in future treatment of symptoms or diseases involving the lower gut. | Chun-Qiu Chen Jakub Fichna Mohammad Bashashati Yong-Yu Li Martin Storr | 2011 | World Journal of Gastroenterology2011，17，34： | 13 |
| 3 | Inhibition of ileal bile acid transporter:An emerging therapeutic strategy for chronic idiopathic constipation显示文摘Chronic idiopathic constipation is a common disorder of the gastrointestinal tract that encompasses a wide profile of symptoms. Current treatment options for chronic idiopathic constipation are of limited value; therefore, a novel strategy is necessary with an increased effectiveness and safety. Recently, the inhibition of the ileal bile acid transporter has become a promising target for constipation-associated diseases. Enhanced delivery of bile acids into the colon achieves an accelerated colonic transit, increased stool frequency, and relief of constipationrelated symptoms. This article provides insight into the mechanism of action of ileal bile acid transporter inhibitors and discusses their potential clinical use for pharmacotherapy of constipation in chronic idiopathic constipation. | Paula Mosińska Jakub Fichna Martin Storr | 2015 | World Journal of Gastroenterology2015，21，24： | 4 |
| 4 | Antinociceptive effects of novel melatonin receptor agonists in mouse models of abdominal pain显示文摘AIM: To characterize the antinociceptive action of the novel melatonin receptor(MT) agonists, Neu-P11 and Neu-P12 in animal models of visceral pain. METHODS: Visceral pain was induced by intracolonic(ic) application of mustard oil or capsaicin solution or by intraperitoneal(ip) administration of acetic acid. Neu-P11, Neu-P12, or melatonin were given ip or orally and their effects on pain-induced behavioral responses were evaluated. To identify the receptors involved, thenon-selective MT1/MT2 receptor antagonist luzindole, the MT2 receptor antagonist 4-P-PDOT, or the μ-opioid receptor antagonist naloxone were injected ip or intracerebroventricularly(icv) prior to the induction of pain. RESULTS: Orally and ip administered melatonin, Neu-P11, and Neu-P12 reduced pain responses in a dose-dependent manner. Neu-P12 was more effective and displayed longer duration of action compared to melatonin. The antinociceptive effects of Neu-P11 or Neu-P12 were antagonized by ip or icv. administered naloxone. Intracerebroventricularly, but not ip administration of luzindole or 4-P-PDOT blocked the antinociceptive actions of Neu-P11 or Neu-P12. CONCLUSION: Neu-P12 produced the most potent and long-lasting antinociceptive effect. Further development of Neu-P12 for future treatment of abdominal pain seems promising. | Chunqiu Chen Jakub Fichna Moshe Laudon Martin Storr | 2014 | World Journal of Gastroenterology2014，20，5： | 3 |
| 5 | Nociceptin effect on intestinal motility depends on opioidreceptor like-1 receptors and nitric oxide synthase colocalization显示文摘AIM: To study the effect of the opioid-receptor like-1(ORL1) agonist nociceptin on gastrointestinal(GI)myenteric neurotransmission and motility. METHODS: Reverse transcriptase- polymerase chain reaction and immunohistochemistry were used to localize nociceptin and ORL1 in mouse tissues. Intracellular electrophysiological recordings of excitatory and inhibitory junction potentials(EJP, IJP) were made in a chambered organ bath. Intestinal motility was measured in vivo. RESULTS: Nociceptin accelerated whole and upper GI transit, but slowed colonic expulsion in vivo in an ORL1-dependent manner, as shown using [Nphe1]NOC and AS ODN pretreatment. ORL1 and nociceptin immunoreactivity were found on enteric neurons. Nociceptin reduced the EJP and the nitric oxide-sensitive slow IJP in an ORL1-dependent manner, whereas the fast IJP was unchanged. Nociceptin further reduced the spatial spreading of the EJP up to 2 cm. CONCLUSION: Compounds acting at ORL1 are good candidates for the future treatment of disorders associated with increased colonic transit, such as diarrhea or diarrhea-predominant irritable bowel syndrome. | Andrei Sibaev Jakub Fichna Dieter Saur Birol Yuece Jean-Pierre Timmermans Martin Storr | 2015 | World Journal of Gastrointestinal Pharmacology and Therapeutics2015，6，3： | 2 |
| 6 | Metabolomics: is it useful for inflammatory bowel diseases?显示文摘 | Martin Storr Hans J. Vogel Rudolf Schicho | 2013 | Current Opinion in Gastroenterology2013，，： | 2 |
| 7 | Cytokine gene polymorphisms are associated with irritable bowel syndrome: a systematic review and meta‐analysis显示文摘 | M. Bashashati N. Rezaei H. Bashashati A. Shafieyoun N. E. Daryani K. A. Sharkey M. Storr | 2012 | Neurogastroenterology & Motility2012，，12： | 2 |
| 8 | Long-term anterior pituitary function in patients with paediatrie Cushing's disease treated with pituitary radiotherapy 显示文摘 | Chan LF Storr HL Plowman PN | 2007 | Eur J Endoerinol2007，156，4： | 1 |
| 9 | Evaluation of a patient empowering hand hygiene programme in the UK显示文摘 | MeGuckin M Wteman R Storr J | | 0，，： | 1 |
| 10 | Activation of cannabinoid receptor 2 reduces inflammation in acute experimental pancreatitis v/a intra-acinar activation of p38 and MK2-dependent mechanisms 显示文摘 | Michler T Storr M Kramer J | 2013 | Am J Physiol Gastrointest Liver Physiol2013，304，2： | 1 |
| 11 | Endomorphins 1 and 2 reduce relaxant non-adrenergic, non-cholinergic neurotransmission in rat gastricfundus显示文摘 | Storr M Gaffal E Schusdziarra V | 2002 | Lire Sei2002，71，： | 1 |
| 12 | 'Clean Care is Safer Care ': the global patient safety challenge 2005 -- 2006 显示文摘 | Pittet D Allegranzi B Storr J | 2006 | Int J Infect Dis2006，10，6： | 1 |
| 13 | Noninvasive ventilation during walk-ing in patients with severe COPD:a randomised cross-over trial显示文摘 | Dreher M Storre JH Windisch W | 2007 | Eur Respir J2007，29，5： | 1 |
| 14 | Blood Material Interactions at the Surfaces of Membranes in Medical Applications 显示文摘 | Deppisch R Storr M Buck R | 1998 | Separation and Purification Technology1998，14，： | 1 |
| 15 | The calpain system and cancer显示文摘 | Storr SJ Carragher NO Frame MC | 2011 | Nature Reviews Cancer2011，，5： | 1 |
| 16 | The first global patient safety challenge 'Clean Care is Safer Care': from launch to current progress and achievements 显示文摘 | Allegranzi B Storr J Dziekan G | 2007 | J Hosp Infect2007，65，2： | 1 |
| 17 | Melatonin reduces non-adrenergic, non-cholinergic relaxant neurotransmission by inhibition of nitric oxide synthase activity in the gastrointestinal tract of rodents in vitro 显示文摘 | Storr M Koppitz P Sibaev A Saur D Kurjak M Franck H | 2002 | J Pineal Res2002，33，2： | 1 |
| 18 | The WHO Clean Care is Safer Care programme: field-testing to enhance sustain- ability and spread of hand hygiene improvements 显示文摘 | Pittet D Allegranzi B Storr J | 2008 | J Infect Public Health2008，1，： | 1 |
| 19 | Infection control as a major World Health Organization priority for developing countries显示文摘 | Pittet D Allegranzi B Storr J | 2008 | J Hosp Infect2008，68，4： | 1 |
| 20 | Expectations of Government's Response to Disaster显示文摘 | Chamlee-- Wright E & Storr VH | 2010 | Public Choice2010，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员